NCT06461156 - A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC) | Biotech Hunter

Enrollment

230

Participants

Timeline

Start Date

July 22, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

March 31, 2027

Conditions

Locally Advanced or Metastatic NSCLC

Interventions

DRUG

HS-10504

HS-10504 will be administered orally once daily in a continuous regimen. Participants will continue treatment until experiencing objective disease progression or meeting other protocol-specified criteria for discontinuation of study treatment.

Trial Locations (1)

Unknown

RECRUITING

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou